Literature DB >> 2708555

Management of monoamine oxidase inhibitor-associated insomnia with trazodone.

A A Nierenberg1, P E Keck.   

Abstract

Monoamine oxidase inhibitors (MAOIs) have been reported to cause or exacerbate insomnia, sometimes requiring discontinuation despite adequate therapeutic response. The authors present a series of 13 cases of MAOI-associated insomnia managed with addition of trazodone. Twelve patients (92%) had an initial positive response, with nine (69%) able to continue on the combination of MAOI and trazodone without intolerable side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2708555

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

Review 1.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

2.  Monoamine oxidase inhibitors: clinical review.

Authors:  R A Remick; C Froese
Journal:  Can Fam Physician       Date:  1990-06       Impact factor: 3.275

3.  Moving on With Monoamine Oxidase Inhibitors.

Authors:  J Alexander Bodkin; Boadie W Dunlop
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

4.  Mindfulness-based cognitive therapy improves polysomnographic and subjective sleep profiles in antidepressant users with sleep complaints.

Authors:  Willoughby B Britton; Patricia L Haynes; Keith W Fridel; Richard R Bootzin
Journal:  Psychother Psychosom       Date:  2012-07-20       Impact factor: 17.659

Review 5.  Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.

Authors:  M Haria; A Fitton; D McTavish
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

Review 6.  Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.

Authors:  Y Lecrubier
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

Review 7.  Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?

Authors:  Dieter Riemann
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.